Centenara Labs

Executive Summary

Centenara Labs, headquartered in Baar, Switzerland, is a private biotech company dedicated to developing and investing in therapies targeting geriatric diseases with the mission to expand healthspan as the global population ages. Founded in 2020, the company operates at the intersection of AI/machine learning and drug discovery, leveraging computational approaches to identify novel interventions for age-related conditions. Currently in Phase 1 stage, Centenara Labs is focused on building a pipeline of candidates that address fundamental aging mechanisms, aiming to promote overall health and longevity. The company's strategy combines internal R&D with strategic investments in complementary therapeutic platforms. With a lean team and no disclosed funding rounds, Centenara Labs represents an early-stage opportunity in the rapidly growing longevity biotech sector. Its progress will depend on advancing preclinical programs into clinical development and securing partnerships or financing to support further growth.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Lead Candidate IND Filing60% success
• Q3 2026Series A Funding Round Closure70% success
• Q2 2026Publication of Preclinical Efficacy Data in Peer-Reviewed Journal50% success